ClinicalTrials.Veeva

Menu

Understanding Host-pathogen Interaction in the Respiratory Mucosa During Pregnancy

The Washington University logo

The Washington University

Status

Completed

Conditions

Innate Inflammatory Response
Pregnancy Related

Treatments

Other: Nasal brush sampling

Study type

Observational

Funder types

Other

Identifiers

NCT04962477
202107016

Details and patient eligibility

About

The clinical presentation of the ongoing coronavirus disease-19 (COVID-19) pandemic in pregnant women is unique with more asymptomatic infection, higher morbidity when symptomatic, yet without a difference in mortality rate. This is strikingly different from the high mortality observed during the past influenza A pandemics. Though both influenza A virus (IAV) and SARS-CoV-2 are single-stranded RNA viruses, the exquisite vulnerability of pregnant women to influenza A but not COVID-19 remains a mystery. Our objective, therefore, is to determine the mechanisms that predispose pregnant women to severe influenza A but confer protection against SARS-CoV-2 infection by examining the viral entry factors and innate immune response mechanisms in the nasal epithelium of pregnant vs. non-pregnant age-matched women.

Enrollment

48 patients

Sex

Female

Ages

18 to 45 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

  • Healthy, uncomplicated pregnant subjects in the third trimester ((≥ 28 ≤ 41 weeks' gestation)
  • Healthy non-pregnant adult female volunteers between the ages of 18 - 45 years.
  • Between 18-45 years old
  • Able to provide consent

Exclusion criteria

  • Patients in labor
  • Critically ill patients needing intubation and mechanical ventilation
  • Patients with fever or influenza-like illness
  • H/o epistaxis or rhinosinusitis
  • Nasal polyposis and deviated nasal septum
  • Preeclampsia and chronic hypertension
  • Use of anti-hypertensives
  • Ongoing seasonal allergy
  • H/o asthma
  • Recent recovery from SARS-CoV-2 or influenza A infection (≤ 4 weeks)
  • Recent receipt of either COVID-19 or influenza A vaccine (≤ 4 weeks)
  • Use of immunosuppressive medications
  • Use of inhaled corticosteroids
  • Use of hormonal contraceptives in non-pregnant population
  • Allergy to local anesthetic

Trial design

48 participants in 2 patient groups

Pregnant
Treatment:
Other: Nasal brush sampling
Non-pregnant
Treatment:
Other: Nasal brush sampling

Trial contacts and locations

1

Loading...

Central trial contact

Arvind Palanisamy, MD; Cristina Bowman

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems